Age: 83
Gender: Male
Diagnosis: Type 2 Diabetes Mellitus, Hypertensive Heart Disease, Chronic Kidney Disease (Stage 5), and Toxocariasis
Clinical Status: Requiring daily hemodialysis
At 83 years old, the patient presented with a critical combination of conditions affecting multiple organ systems. He had long-standing Type 2 diabetes and high blood pressure (hypertension), both of which are known to damage the kidneys and other organs over time. The result was end-stage chronic kidney disease (CKD)—the final stage of kidney failure, where the kidneys are no longer able to remove waste products or maintain fluid and electrolyte balance. The patient was entirely dependent on daily hemodialysis, a mechanical process to filter his blood.
As if this weren’t enough, blood tests also revealed the presence of toxocariasis, a parasitic infection, along with widespread signs of inflammation, anemia, and liver dysfunction. Conventional treatments had reached their limits. At this stage, improving quality of life and preserving remaining organ function required a regenerative approach.
The patient received a carefully administered intravenous infusion of mesenchymal stem cells (MSCs) derived from healthy donors. These adult stem cells are capable of identifying damaged tissue in the body, reducing inflammation, repairing organs at the cellular level, and reactivating the body’s own healing mechanisms. Unlike organ transplants, MSCs do not require tissue matching or immunosuppressive drugs because they work by communication and coordination, not by replacing whole organs.
Once in the bloodstream, these cells migrate to the areas where they are most needed—including the kidneys, pancreas, immune system, and bone marrow—and begin a multifaceted process of repair and regeneration.
Before therapy, blood work painted a clear picture of critical illness. The patient's serum creatinine, a marker for kidney function, was alarmingly high at 8.62 mg/dL, well above the normal range of 0.6–1.6 mg/dL. This indicated that the kidneys were barely functioning. His eGFR (estimated glomerular filtration rate) was just 8.62 mL/min/1.73m², a value consistent with kidney failure. Urea, another waste product filtered by the kidneys, was also elevated at 87.0 mg/dL.
Electrolytes—specifically potassium, sodium, and chloride—were all below normal. These minerals are essential for nerve signaling, muscle contraction, and fluid balance, and the kidneys are responsible for maintaining their levels. The disturbance confirmed that the kidneys had lost their regulatory function.
The patient’s blood glucose was moderately elevated at 117 mg/dL, and hemoglobin was low, indicating anemia—a common result of damaged kidneys failing to produce enough erythropoietin, the hormone that tells the bone marrow to make red blood cells.
Perhaps most telling was the immune profile. The patient had lymphopenia (low lymphocyte count), monocytosis (high monocytes), and neutrophilia (high neutrophils). This constellation suggested the immune system was fighting a chronic infection—which, in this case, was confirmed as toxocariasis, a parasitic disease known to cause long-standing immune activation.
This baseline snapshot showed systemic decompensation: the kidneys were failing, blood sugar was poorly regulated, the immune system was overactivated, and inflammation was widespread.
Just twelve days after the first MSC infusion, the patient began showing significant improvement. His creatinine levels dropped to 7.24 mg/dL, a meaningful decrease that suggested the kidneys were beginning to recover their filtering capacity. Urea also fell slightly to 82.4 mg/dL, and other indicators of kidney function stabilized.
While his eGFR remained low, it was no longer worsening, and early corrections in electrolyte balance suggested that kidney signaling was beginning to normalize. The white blood cell counts showed early signs of immune regulation, indicating that the immune system was being recalibrated away from constant inflammation.
These results confirmed that the stem cells had begun their regenerative work: reducing inflammation, clearing cellular debris, restoring signaling pathways, and initiating tissue repair.
Following a second MSC infusion, the improvements became more pronounced. Creatinine levels fell again to 6.46 mg/dL, and eGFR rose to 8.46 mL/min/1.73m², indicating enhanced filtration performance. Urea showed a temporary spike to 90.6 mg/dL, which may have been due to increased protein metabolism or detoxification activity—not uncommon during cellular regeneration.
Red blood cell counts also began to improve. The patient’s hemoglobin was climbing without the use of iron supplements or erythropoietin injections. This suggested that the kidneys were beginning to resume their hormonal communication with the bone marrow.
Overall, this stage reflected tissue-level healing and increasing physiological stability. The patient's system was clearly responding to treatment, with both measurable lab results and clinical improvements in how he felt.
By the time of the final follow-up, the patient’s improvement was unmistakable. Creatinine dropped further to 6.00 mg/dL, the best reading since the start of treatment. Urea decreased to 75.2 mg/dL, and potassium levels returned to normal, indicating a restored ability of the kidneys to manage electrolytes.
More remarkably, blood glucose normalized to 118 mg/dL, suggesting that the pancreas—damaged by years of diabetes—had regained some of its functional capacity. The hemoglobin concentration reached 13.2 g/dL, marking a return to normal oxygen-carrying capacity and resolving the patient’s anemia.
This data confirmed a system-wide regeneration—not just symptom control, but true biological repair.
The infused mesenchymal stem cells acted as both healers and coordinators within the patient’s body. In the kidneys, they reduced inflammation, repaired damaged nephrons, and improved the organ’s ability to regulate waste and electrolyte balance. This directly led to reduced creatinine and normalized potassium and sodium levels.
In the immune system, MSCs restored balance. They did not simply suppress immune activity, but reprogrammed the system to shift from a state of constant inflammation toward one of regulation and healing. The immune cell counts stabilized, and the systemic effects of chronic infection began to recede.
The therapy also impacted blood production. By restoring communication between the kidneys and bone marrow, MSCs helped stimulate the natural production of red blood cells. As a result, the patient’s hemoglobin rose without external supplementation, resolving the fatigue and weakness associated with anemia.
Perhaps most notably, the stem cells also improved pancreatic function. The pancreas contains stem-like progenitor cells that, under the right conditions, can become insulin-producing beta cells. In chronic diabetes, this regeneration process often fails. MSC therapy reactivated this dormant pathway, enabling the pancreas to resume insulin regulation—as reflected in the patient’s normalized blood sugar.
These combined effects represent true organ-level regeneration, driven by the ability of stem cells to communicate with native tissues, direct repair, and guide the body back to equilibrium.
This case demonstrates the profound potential of mesenchymal stem cell therapy to reverse the effects of advanced, multi-system disease. In a patient with chronic kidney failure, uncontrolled diabetes, anemia, inflammation, and parasitic infection, stem cell treatment restored measurable function across all major affected systems.
Creatinine decreased by over 30%. Hemoglobin normalized. Glucose stabilized. Electrolytes rebalanced.
These are not temporary fixes—they are signs of biological recovery. Stem cell therapy did not merely mask symptoms but reversed the underlying damage that decades of chronic disease had caused.
For patients suffering from chronic kidney disease and other degenerative conditions, this case offers real hope—and clear evidence—that regenerative medicine can change the course of disease, restore function, and improve quality of life.
Age Management Systems Asia:
Vietnam Office: 22.D1 Saigon
Pearl Villa, Ward 22,
Binh Thanh district,
Ho Chi Minh city, Vietnam
USA Office:
30 Wall Street, 8th Floor,
New York, NY 10005-2205,
USA
Contact us:
WhatsApp: +380934880800
Email: info@amsabiotech.com